Overview

Epoetin Alfa for HIV-Associated Neuropathy Trial

Status:
Withdrawn
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of epoetin alfa on HIV-associated neuropathy by measuring changes in nerve fiber density and pain ratings.
Phase:
Phase 2
Details
Lead Sponsor:
Washington University School of Medicine
Collaborators:
National Institute of Neurological Disorders and Stroke (NINDS)
Ortho Biotech Clinical Affairs, L.L.C.
PPD
Treatments:
Epoetin Alfa